Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu Andrew X.; Finn Richard S.; Edeline Julien; Cattan Stephane; Ogasawara Sadahisa; Palmer Daniel; Verslype Chris; Zagonel Vittorina; Fartoux Laetitia; Vogel Arndt; Sarker Debashis; Verset Gontran; Chan Stephen L.; Knox Jennifer; Daniele Bruno; Webber Andrea L.; Ebbinghaus Scot W.; Ma Junshui; Siegel Abby B.; Cheng Ann-Lii; Kudo Masatoshi

首页> 外文期刊>The lancet oncology >Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

【24h】

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

机译：Pembrolizumab在先前用Sorafenib治疗的先进肝细胞癌（Keynote-224）：非随机开放标记相2试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population.

机译：背景技术免疫检查点阻断治疗表明了患有晚期肝细胞癌患者的有希望的结果。我们的旨在评估Pembrozumab在该患者人口中的疗效和安全性。

著录项

来源
《The lancet oncology》 |2018年第7期|共13页
作者
Zhu Andrew X.; Finn Richard S.; Edeline Julien; Cattan Stephane; Ogasawara Sadahisa; Palmer Daniel; Verslype Chris; Zagonel Vittorina; Fartoux Laetitia; Vogel Arndt; Sarker Debashis; Verset Gontran; Chan Stephen L.; Knox Jennifer; Daniele Bruno; Webber Andrea L.; Ebbinghaus Scot W.; Ma Junshui; Siegel Abby B.; Cheng Ann-Lii; Kudo Masatoshi;
展开▼
作者单位

Harvard Med Sch Dept Med Boston MA 02114 USA;

Univ Calif Los Angeles Dept Med Los Angeles CA USA;

Ctr Eugene Marquis Dept Med Oncol Rennes France;

CHRU Lille Dept Med Oncol &

Gastroenterol Hop Claude Huriez Lille France;

Chiba Univ Grad Sch Med Dept Gastroenterol Chiba Japan;

Univ Liverpool Dept Med Oncol Liverpool Merseyside England;

Univ Hosp Gasthuisberg Dept Hepatol Leuven Belgium;

Ist Oncol Veneto Dept Clin &

Expt Oncol Padua Italy;

Hop Univ Pitie Salpetriere Dept Gastroenterol &

Hepatol Paris France;

Hannover Med Sch Dept Gastroenterol Hepatol &

Endocrinol Hannover Germany;

Kings Coll Hosp London Dept Med Oncol London England;

Hop Erasme Gastrointestinal Oncol Unit Brussels Belgium;

Chinese Univ Hong Kong State Key Lab Oncol South China Dept Clin Oncol Shatin Hong Kong;

Univ Toronto Princess Margaret Canc Ctr Dept Med Oncol Toronto ON Canada;

Azienda Osped Gaetano Rummo Dept Oncol Benevento Italy;

Merck &

Co Inc Dept Global Clin Dev Kenilworth NJ USA;

Merck &

Co Inc Dept Global Clin Dev Kenilworth NJ USA;

Merck &

Co Inc Dept Global Clin Dev Kenilworth NJ USA;

Merck &

Co Inc Dept Global Clin Dev Kenilworth NJ USA;

Natl Taiwan Univ Hosp Dept Med Oncol Taipei Taiwan;

Kindai Univ Fac Med Dept Gastroenterol &

Hepatol Osaka Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [J] . Zhu Andrew X., Finn Richard S., Edeline Julien, The lancet oncology . 2018,第7期

机译：Pembrolizumab在先前用Sorafenib治疗的先进肝细胞癌（Keynote-224）：非随机开放标记相2试验
2. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J] . Atkins Michael B., Plimack Elizabeth R., Puzanov Igor, The lancet oncology . 2018,第3期

机译：Axitinib与Pembrolizumab联合患者患有先进的肾细胞癌：非随机性，开放标签，剂量发现和剂量扩展阶段1B试验
3. Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018; 19: 405-15 [J] . Di Nunno Vincenzo, Santoni Matteo, Massari Francesco European urology . 2018,第2期

机译：回复：迈克尔B.阿特金斯，伊丽莎白r. plimack，igor puzanov等。 Axitinib与Pembrolizumab联合肾细胞癌症患者：非随机性，开放标签，剂量发现和剂量 - 膨胀期1B试验。柳叶刀oncol 2018; 19：405-15
4. Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib [C] . C. Schraml, N.F. Schwenzer, H. Rempp, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. A multicentre open-label phase-I/randomised phase-II study to evaluate safety pharmacokinetics and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [O] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, 2018

机译：一项多中心开放标签I期/随机II期研究评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性药代动力学和疗效
7. Efficacy and safety of single agent sunitinib in treating Sorafenib Refractory Advanced Hepatocellular Carcinoma Patients: a prospective, open-label, phase II study [O] . Tang, YF, Cheung, TT, Fan, ST, 2013

机译：单药舒尼替尼治疗索拉非尼难治性晚期肝细胞癌患者的疗效和安全性：前瞻性，开放性，II期研究

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅